The present study aimed to investigate the expression of pyrroline-5-carboxylate reductase 1 (P5CR1) protein in lung adenocarcinoma and paracancerous tissues and to explore the effect of silencing the encoding gene PYCR1 on the proliferation, migration, invasion, and cisplatin sensitivity in lung adenocarcinoma cells, thereby providing a novel therapeutic target for the treatment of the disease. Immunohistochemistry staining was used to detect the P5CR1 protein expression in lung adenocarcinoma and paracancerous tissues, and statistical analysis evaluated the correlation between P5CR1 protein expression and gender, age, tissue part, or pathological grade. The CCK8 assay was performed to detect the proliferation and cisplatin sensitivity, while the effect of PYCR1 on the migration and invasion of lung adenocarcinoma cells was detected by scratch test and transwell chamber assay. The findings demonstrated that the P5CR1 protein expression was significantly elevated in lung adenocarcinoma tissues and correlated with the pathological grade, whereas no significant correlation was established between the protein expression and gender, age, or tissue part. Furthermore, after PYCR1 gene silencing, the proliferation and invasion were significantly suppressed, while the sensitivity to cisplatin was significantly enhanced. Therefore, it can be speculated that the PYCR1 gene affects the biological behavior of lung adenocarcinoma and cisplatin resistance, serving as a potential therapeutic target for lung adenocarcinoma.
BackgroundThe protein encoded by the selenoprotein S gene is considered to be an anti‐inflammatory and antioxidant protein and is involved in a variety of diseases. Therefore, we want to study the distribution characteristics of this gene in Chinese diabetic population.MethodsA total of 170 patients with DM (including 100 patients with T2DM and 70 patients with diabetic nephropathy [DN]) and 100 healthy controls (HC) were selected from Haikou People's Hospital (China) between January 2017 and July 2017. The polymorphisms of three SEPS1 genes (SNP ID: rs4965814, rs28665122, and rs34713741) were measured by massARRAY method, while the polymorphisms of SEPS1 genes (SNP ID: rs4965373) were detected by Sanger sequencing.ResultsComparing three groups, the results were the following: (a) There was a significant difference in the genotype and allele distribution of rs34713741 between DN group and HC group and between T2DM group and DN group; For this gene locus, the risk of diabetic nephropathy in healthy individuals with T allele was 0.6 times higher than that in individuals with GG genotype (OR = 0.60, 95% CI: 0.46 ~ 0.77). (b) There was a significant difference in the distribution of rs4975814 genotype between DN group and HC group; for this gene locus, the risk of diabetic nephropathy in healthy individuals with T allele was 2.71 times higher than that in individuals with GG genotype (OR = 2.71, 95% CI: 1.66 ~ 4.45).ConclusionWe conclude that rs34713741 (GT + TT) may be a protective gene for DN and the rs4975814 (GT + TT) may be a susceptibility gene for DN.
Schizophrenia is a chronic and disabling mental disorder characterized by hallucinations, delusions, disorganized speech or behavior, and impaired cognitive ability. Most patients present with highly heterogeneous typical symptoms in late adolescence or early adulthood. 1 A 2016 study showed that schizophrenia's global agestandardized time-point prevalence was about 0.28%, with high early mortality. 2 Moreover, patients with schizophrenia have a high risk of suicide, and their life expectancy is approximately 20 years shorter than in the general population. 3 Intermittent and long-term mental problems, chronic symptoms, and even disability often lead
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.